Harvard Bioscience Inc
HBIO0.753USD
-0.014-1.79%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
33.59MMarket Cap
LossP/E TTM
More Details of Harvard Bioscience Inc Company
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Harvard Bioscience Inc Info
Ticker SymbolHBIO
Company nameHarvard Bioscience Inc
IPO dateOct 21, 2013
CEODuke (John D)
Number of employees330
Security typeOrdinary Share
Fiscal year-endOct 21
Address84 October Hill Rd
CityHOLLISTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01746-1371
Phone15088938999
Websitehttps://www.harvardbioscience.com/
Ticker SymbolHBIO
IPO dateOct 21, 2013
CEODuke (John D)
Company Executives of Harvard Bioscience Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
421.13K
+35.36%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
110.00K
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
87.29K
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
421.13K
+35.36%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
110.00K
--
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
87.29K
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Instruments, equipment, software and accessories
18.18M
88.89%
Service, maintenance and warranty contracts
2.27M
11.11%
By RegionUSD
Name
Revenue
Proportion
United States
9.66M
47.22%
Europe, Middle East and Africa
6.59M
32.22%
China
2.45M
11.99%
Rest of Asia
1.33M
6.52%
Americas - Other
422.00K
2.06%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Instruments, equipment, software and accessories
18.18M
88.89%
Service, maintenance and warranty contracts
2.27M
11.11%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AMH Equity, Ltd.
7.51%
Weber Capital Management, LLC
7.18%
Harvey Partners, LLC
4.60%
The Vanguard Group, Inc.
4.15%
Green (James W)
3.67%
Other
72.88%
Shareholders
Shareholders
Proportion
AMH Equity, Ltd.
7.51%
Weber Capital Management, LLC
7.18%
Harvey Partners, LLC
4.60%
The Vanguard Group, Inc.
4.15%
Green (James W)
3.67%
Other
72.88%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.67%
Investment Advisor
11.36%
Individual Investor
10.50%
Investment Advisor/Hedge Fund
10.39%
Venture Capital
7.18%
Pension Fund
2.04%
Research Firm
0.15%
Family Office
0.07%
Bank and Trust
0.01%
Other
40.63%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
201
25.97M
58.27%
-8.70M
2025Q2
214
34.64M
78.35%
-7.01M
2025Q1
216
35.57M
80.46%
-4.66M
2024Q4
216
39.38M
90.28%
+2.67M
2024Q3
217
37.20M
85.38%
-773.14K
2024Q2
216
36.12M
83.22%
-2.57M
2024Q1
216
36.60M
84.34%
-2.39M
2023Q4
219
36.53M
85.65%
-2.57M
2023Q3
223
36.90M
86.54%
-1.23M
2023Q2
223
36.47M
86.49%
-881.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AMH Equity, Ltd.
4.05M
9.09%
+538.83K
+15.36%
Aug 06, 2025
Weber Capital Management, LLC
3.20M
7.19%
+683.45K
+27.15%
Mar 31, 2025
Harvey Partners, LLC
2.14M
4.81%
-46.40K
-2.12%
Jun 30, 2025
The Vanguard Group, Inc.
1.85M
4.16%
-284.86K
-13.32%
Jun 30, 2025
Green (James W)
1.64M
3.68%
-392.52K
-19.34%
Aug 15, 2025
272 Capital LLC
1.56M
3.49%
+1.56M
--
Sep 30, 2024
Acadian Asset Management LLC
1.04M
2.33%
-37.84K
-3.51%
Jun 30, 2025
Duke (John D.)
1.00M
2.25%
+1.00M
--
Aug 08, 2025
Meros Investment Management, LP
919.95K
2.07%
+125.27K
+15.76%
Jun 30, 2025
Florida State Board of Administration
910.00K
2.04%
+130.66K
+16.77%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin US Small Cap Multifactor Index ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Lattice Hartford Multifactor Small Cap ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Proshares Ultra Russell 2000
0%
View more
Franklin US Small Cap Multifactor Index ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Lattice Hartford Multifactor Small Cap ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Harvard Bioscience Inc?
The top five shareholders of Harvard Bioscience Inc are:
AMH Equity, Ltd. holds 4.05M shares, accounting for 9.09% of the total shares.
Weber Capital Management, LLC holds 3.20M shares, accounting for 7.19% of the total shares.
Harvey Partners, LLC holds 2.14M shares, accounting for 4.81% of the total shares.
The Vanguard Group, Inc. holds 1.85M shares, accounting for 4.16% of the total shares.
Green (James W) holds 1.64M shares, accounting for 3.68% of the total shares.
AMH Equity, Ltd. holds 4.05M shares, accounting for 9.09% of the total shares.
Weber Capital Management, LLC holds 3.20M shares, accounting for 7.19% of the total shares.
Harvey Partners, LLC holds 2.14M shares, accounting for 4.81% of the total shares.
The Vanguard Group, Inc. holds 1.85M shares, accounting for 4.16% of the total shares.
Green (James W) holds 1.64M shares, accounting for 3.68% of the total shares.
What are the top three shareholder types of Harvard Bioscience Inc?
The top three shareholder types of Harvard Bioscience Inc are:
AMH Equity, Ltd.
Weber Capital Management, LLC
Harvey Partners, LLC
AMH Equity, Ltd.
Weber Capital Management, LLC
Harvey Partners, LLC
How many institutions hold shares of Harvard Bioscience Inc (HBIO)?
As of 2025Q3, 201 institutions hold shares of Harvard Bioscience Inc, with a combined market value of approximately 25.97M, accounting for 58.27% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -20.08%.
What is the biggest source of revenue for Harvard Bioscience Inc?
In FY2025Q2, the Instruments, equipment, software and accessories business generated the highest revenue for Harvard Bioscience Inc, amounting to 18.18M and accounting for 88.89% of total revenue.
